Tamara Vokes to Hypoparathyroidism
This is a "connection" page, showing publications Tamara Vokes has written about Hypoparathyroidism.
Connection Strength
4.884
-
Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019 11 01; 104(11):5136-5147.
Score: 0.600
-
Quality of Life in Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018 12; 47(4):855-864.
Score: 0.558
-
Quality of life in hypoparathyroidism. Bone. 2019 03; 120:542-547.
Score: 0.556
-
Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. J Clin Endocrinol Metab. 2018 02 01; 103(2):722-731.
Score: 0.532
-
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial. J Bone Miner Res. 2026 Sep 24; 41(10):1069-1079.
Score: 0.242
-
Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension. J Clin Endocrinol Metab. 2026 Mar 17; 111(4):945-952.
Score: 0.233
-
Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism. Eur J Endocrinol. 2025 Sep 30; 193(4):428-439.
Score: 0.226
-
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
Score: 0.223
-
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):951-960.
Score: 0.218
-
Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey. J Bone Miner Res. 2022 12; 37(12):2630-2641.
Score: 0.185
-
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023 01; 38(1):14-25.
Score: 0.185
-
Management of Hypoparathyroidism. J Bone Miner Res. 2022 12; 37(12):2663-2677.
Score: 0.185
-
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022 01 01; 107(1):e372-e385.
Score: 0.174
-
The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord. 2021 Nov 20; 21(1):232.
Score: 0.173
-
Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-µg or 50-µg Daily Doses. Clin Ther. 2017 Oct; 39(10):2096-2102.
Score: 0.130
-
Hypoparathyroidism. Nat Rev Dis Primers. 2017 08 31; 3:17055.
Score: 0.129
-
Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017 Jan; 55(1):273-282.
Score: 0.121
-
Presentation of Hypoparathyroidism: Etiologies and Clinical Features. J Clin Endocrinol Metab. 2016 06; 101(6):2300-12.
Score: 0.116
-
Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):275-83.
Score: 0.098